article
27 May 2024 | By Dr Heather O’Neill (Caris Life Sciences), Dr Milan Radovich (Caris Life Sciences), Ellen Capon (Drug Target Review)
In this Q&A, senior leaders at Caris Life Sciences discuss how the company is advancing precision medicine by integrating ADCs into patient-specific cancer treatment plans, focusing on novel target discovery through comprehensive molecular profiling and clinico-genomic data.